Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma

Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma

Publication date: Mar 06, 2019

This phase I trial studies the side effects and best dose of a modified virus called VSV-IFNbetaTYRP1 in treating patients with stage III-IV melanoma. The vesicular stomatitis virus (VSV) has been altered to include two extra genes: human interferon beta (hIFNbeta), which may protect normal healthy cells from becoming infected with the virus, and TYRP1, which is expressed mainly in melanocytes (specialized skin cell that produces the protective skin-darkening pigment melanin) and melanoma tumor cells, and may trigger a strong immune response to kill the melanoma tumor cells.

Concepts Keywords
Ablation Metastatic ocular melanoma
Adrenal Insufficiency Tumors
Alanine Aminotransferase Preliminary tumor
ALT IV melanoma
ANC Patient disease
Antigen MRI
APTT Pharmacodynamics
Ascites Chemotherapy
Aspartate Transaminase Ultrasound
AST Antibodies
Bilirubin Radiation
Biomarker Magnetic resonance imaging
Biopsied Metastasis
Biopsy Cancer immunotherapy
Blood Radiation therapy
BRAF Immunotherapy
Central Nervous System Indiana vesiculovirus
Chemotherapy Uveal melanoma
Cohort Oncology
Concurrent RTT
Contraception Health
Cooperative Group Cancer
Creatinine Melanoma
Cytokine Medicine
Cytologically Immunotherapy
Direct Injection Organ transplant
Enzyme Radiotherapy
Exome Chemotherapy
FDA Vaccine therapies
Hemoglobin Contraception
Histologically Radiation therapy
IFN Gamma Rash
IM Melanoma vesicular stomatitis
Immune Cells Uncontrolled intercurrent illness
Immune Deficiency Hepatitis hepatitis infection
Immunodeficiency History active tuberculosis
Immunohistochemistry Tumor
Immunosuppressive Agents Cervical cancers
Immunotherapy
INR
Interferon Beta
Intracellular
Intravenous
Intravenously
Lesion
Leukemia
Liver
Magnetic Resonance Imaging
Malignant Melanoma
Maximum Tolerated Dose
MEK
Melanin
Melanocytes
Melanoma
Metastases
Metastasis
Metastatic
Modality
Monoclonal Antibodies
Mouthwash
MRI
Neoantigen
Ocular Melanoma
Oncology
Organ
PBL
PCR
Pharmacodynamics
Pharmacokinetic
Physical Examination
Pigment
Platelet Count
Polymerase Chain Reaction
Pregnancy Test
Progressive
Protocol
Radiation Therapy
Radiotherapy
Rash
Recombinant
Reverse Transcriptase
Ribonucleic Acid
RNA
RT
Serum
Splenectomy
Splenic
Staining
Steroid Medication
Subcutaneous
Systemic Therapy
Targeted Therapies
Toxicity
Transcriptome
Transfusion
Tumor
Tyrosinase
Ultrasound
Urine
Urine Test
Vaccine
Vesicular Stomatitis Virus
Viral
Viral Shedding
Viremia
Virus
VSV

Semantics

Type Source Name
gene UNIPROT ALG3
gene UNIPROT NR4A2
disease MESH CNS disease
gene UNIPROT NR4A3
gene UNIPROT SLC35G1
drug DRUGBANK Creatinine
drug DRUGBANK Prothrombin
gene UNIPROT SLC17A5
drug DRUGBANK L-Alanine
disease MESH growth
disease DOID portal vein thrombosis
disease MESH diagnosis
disease DOID ocular melanoma
disease DOID Cutaneous melanoma
disease MESH disease progression
gene UNIPROT BRAF
gene UNIPROT MAP2K7
gene UNIPROT NODAL
disease DOID mucosal melanoma
disease MESH metastasis
gene UNIPROT CYREN
disease MESH ascites
disease MESH adrenal insufficiency
disease MESH leukemia
disease DOID leukemia
gene UNIPROT CTLA4
disease MESH seizure disorder
disease DOID coronary artery disease
disease MESH coronary artery disease
disease DOID hypertension
disease MESH hypertension
disease MESH cardiac arrhythmia
disease MESH Unstable angina pectoris
disease MESH congestive heart failure
disease DOID congestive heart failure
disease MESH infection
disease MESH skin cancers
disease DOID hepatitis C infection
disease MESH second malignancy
pathway BSID Tuberculosis
disease DOID chronic hepatitis B
disease MESH chronic hepatitis B
disease DOID tuberculosis
disease MESH tuberculosis
pathway BSID Infectious disease
disease DOID infectious disease
disease MESH infectious disease
disease DOID rash
disease MESH tumor
disease MESH vesicular stomatitis
gene UNIPROT TYRP1
gene UNIPROT BEST1
pathway BSID Melanoma
disease MESH Melanoma
disease DOID Melanoma

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *